Skip to main content
OTCMKTS:IPAH

Interpharm Competitors

$0.0005
0.00 (0.00 %)
(As of 05/14/2021 02:21 PM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.00
Volume100 shs
Average Volume31,881 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta3.28

Competitors

Interpharm (OTCMKTS:IPAH) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying IPAH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Interpharm, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Interpharm (OTCMKTS:IPAH) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk and Volatility

Interpharm has a beta of 3.28, meaning that its stock price is 228% more volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500.

Profitability

This table compares Interpharm and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InterpharmN/AN/AN/A
AcusphereN/AN/AN/A

Valuation & Earnings

This table compares Interpharm and Acusphere's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterpharmN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Interpharm and Acusphere, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Interpharm0000N/A
Acusphere0000N/A

Summary

Interpharm beats Acusphere on 1 of the 1 factors compared between the two stocks.

Interpharm (OTCMKTS:IPAH) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk and Volatility

Interpharm has a beta of 3.28, meaning that its stock price is 228% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, meaning that its stock price is 177% more volatile than the S&P 500.

Profitability

This table compares Interpharm and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InterpharmN/AN/AN/A
AffymaxN/AN/AN/A

Valuation & Earnings

This table compares Interpharm and Affymax's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterpharmN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Interpharm and Affymax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Interpharm0000N/A
Affymax0000N/A

Summary

Interpharm beats Affymax on 1 of the 1 factors compared between the two stocks.

Interpharm (OTCMKTS:IPAH) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk and Volatility

Interpharm has a beta of 3.28, meaning that its stock price is 228% more volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500.

Profitability

This table compares Interpharm and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InterpharmN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Interpharm and ARYx Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterpharmN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Interpharm and ARYx Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Interpharm0000N/A
ARYx Therapeutics0000N/A

Summary

Interpharm beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

Interpharm (OTCMKTS:IPAH) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk and Volatility

Interpharm has a beta of 3.28, meaning that its stock price is 228% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, meaning that its stock price is 971% less volatile than the S&P 500.

Profitability

This table compares Interpharm and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InterpharmN/AN/AN/A
AtheroNovaN/AN/AN/A

Valuation & Earnings

This table compares Interpharm and AtheroNova's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterpharmN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Interpharm and AtheroNova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Interpharm0000N/A
AtheroNova0000N/A

Summary

Interpharm beats AtheroNova on 1 of the 1 factors compared between the two stocks.

Interpharm (OTCMKTS:IPAH) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk and Volatility

Interpharm has a beta of 3.28, meaning that its stock price is 228% more volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, meaning that its stock price is 1,609% more volatile than the S&P 500.

Profitability

This table compares Interpharm and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InterpharmN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

Valuation & Earnings

This table compares Interpharm and China Botanic Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterpharmN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Interpharm and China Botanic Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Interpharm0000N/A
China Botanic Pharmaceutical0000N/A

Summary

China Botanic Pharmaceutical beats Interpharm on 1 of the 1 factors compared between the two stocks.

Interpharm (OTCMKTS:IPAH) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk and Volatility

Interpharm has a beta of 3.28, meaning that its stock price is 228% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, meaning that its stock price is 1,238% more volatile than the S&P 500.

Profitability

This table compares Interpharm and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InterpharmN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Valuation & Earnings

This table compares Interpharm and China Dongsheng International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterpharmN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Interpharm and China Dongsheng International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Interpharm0000N/A
China Dongsheng International0000N/A

Summary

China Dongsheng International beats Interpharm on 1 of the 1 factors compared between the two stocks.


Interpharm Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00High Trading Volume
Gap Down
ARYX
ARYx Therapeutics
0.0$0.02flat$0.00N/A0.00High Trading Volume
Gap Up
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.95flat$0.00N/A0.00Gap Down
HRBR
Harbor Diversified
0.0$1.70flat$0.00$263.61 million0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.